Phenytoin Disposition and Toxicity: Role of Pharmacogenetic and Interethnic Factors

References

• Francis J., Burnham W. M. [3H]Phenytoin identifies a novel anticonvulsant-binding domain on voltage-dependent sodium channels. Mol. Pharmacol. 1992; 42: 1097–1103
   PubMed Web of Science ®Google Scholar
• Richens A. Clinical pharmacokinetics of phenytoin. Clin. Pharma-cokinet. 1979; 4: 153–169
   PubMed Web of Science ®Google Scholar
• Jones G. L., Wimbish G. H.W. E. McIntosh, Phenytoin: Basic and clinical pharmacology. Med. Res. Rev. 1983; 3: 383
   PubMed Web of Science ®Google Scholar
• Levine M., Chang T. McIntosh, Phenytoin: Basic and clinical pharmacology. Med. Res. Rev. 1983; 3: 383
   PubMed Web of Science ®Google Scholar
• Nation R. L., Evans A. M., Milne R. W. Pharmacokinetic drug interactions with phenytoin (part I). Clin. Pharmacokinet. 1990; 18: 37
   PubMed Web of Science ®Google Scholar
• Nation R. L., Evans A. M., Milne R. W. Pharmacokinetic drug interactions with phenytoin (part II). Clin. Pharmacokinet. 1990; 18: 131
   PubMed Web of Science ®Google Scholar
• Inaba T. Phenytoin: Pharmacogenetic polymorphism of 4′-hydroxy-lation. Pharmacol. Ther. 1990; 46: 341
   PubMed Web of Science ®Google Scholar
• Aronson J. K., Hardman M., Reynolds D. J. M. ABC of monitoring drug therapy: Phenytoin. Br. Med. J. 1992; 305: 1215
   PubMed Web of Science ®Google Scholar
• Pryka R. D., Rodvold K. A., Erdman S. M. An updated comparison of drug dosing methods, Part I: Phenytoin. Clin. Pharmacokinet. 1991; 20: 209
   PubMed Web of Science ®Google Scholar
• Fritz S., Lindner W., Roots I., Frey B. M., Kupfer A. Stereochemistry of aromatic phenytoin hydroxylation in various drug hy-droxylation phenotypes in humans. J. Pharmacol. Exp. Ther. 1987; 241: 615
   PubMed Web of Science ®Google Scholar
• Guengerich F. P. Human cytochrome P-450 enzymes. Life Sci. 1992; 50: 1471
   PubMed Web of Science ®Google Scholar
• Veronese M. E., Mackenzie P. I., Doecke C. J., Mc M. E., Miners J. O., Birkett D. J. Tolbutamide and phenytoin hydroxy-lations by cDNA-expressed human liver cytochrome P4502C9. Bio-chem. Biophys. Res. Commun. 1991; 175: 1112
   PubMed Web of Science ®Google Scholar
• Veronese M. E., Doecke C. J., Mackenzie P. I., Mc M. E., Miners J. O., Rees D. L. P., Gasser R., Meyer U. A., Birkett D. J. Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochem. J. 1993; 289: 533
   PubMed Web of Science ®Google Scholar
• Brian W. R., Srivastava P. K., Umbenhauer D. R., Lloyd R. S., Guengerich F. P. Expression of a human liver cytochrome P450 protein with tolbutamide hydroxylase activity in. Saccharomyces cereBiochemistr. 1989; 28: 4993
   Google Scholar
• Relling M. V., Aoyama T., Gonzalez F. J., Meyer U. A. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J. Pharmacol. Exp. Ther. 1990; 252: 442
   PubMed Web of Science ®Google Scholar
• Doecke C. J., Veronese M. E., Pond S. M., Miners J. O., Birkett D. J., Sansom L. N., Mc M. E. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br. J. Clin. Pharmacol. 1991; 31: 125
   PubMed Web of Science ®Google Scholar
• Romkes M., Faletto M. B., Blaisdell J. A., Raucy J. L., Goldstein J. A. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistr. 1991; 30: 3247
   PubMed Web of Science ®Google Scholar
• Tassaneeyakul W., Veronese M. E., Birkett D. J., Doecke C. J., Mc M. E., Sansom L. N., Miners J. O. Co-regulation of phenytoin and tolbutamide metabolism in humans. Br. J. Clin. Pharmacol. 1992; 34: 494
   PubMed Web of Science ®Google Scholar
• Goldstein J. A., Faletto M. B., Romkes M., Sullivan T. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistr. 1994; 33: 1743
   PubMed Web of Science ®Google Scholar
• Chen L. S., Yasumori T., Yamazoe Y., Kato R. Hepatic microsomal tolbutamide hydroxylation in Japanese: In vitro evidence for rapid and slow metabolizers. Pharmacogenetic. 1993; 3: 77
   PubMedGoogle Scholar
• Rettie A. E., Korzekwa K. R., Kunze K. L., Lawrence R. F., Eddy A. C., Aoyama T., Gelboin H. V., Gonzalez F. J., Trager W. F. Hydroxylation of warfarin by human cDNA expressed cytochrome P-450: A role for P-4502C9 in the etiology of (S)-warfarin drug interactions. Chem. Res. Toxicol. 1992; 5: 54
   PubMed Web of Science ®Google Scholar
• Kaminsky S. M. F., Faletto M. B., Dunbar D. A., Goldstein J. A. Correlation of human cytochrome P4502C substrate specificities with primary structure: Warfarin as a probe. Mol. Pharmacol. 1993; 43: 234
   PubMed Web of Science ®Google Scholar
• de Wolf F. A., Vermeij P., Ferrari M. D., Buruma O. J. S., Breimer D. D. Impairment of phenytoin parahydroxylation as a cause of severe intoxication. Ther. Drug Monit. 1983; 5: 213
   PubMed Web of Science ®Google Scholar
• Peart G. F., Boutagy J., Shenfield G. M. Lack of relationship between tolbutamide metabolism and debrisoquin oxidation phenotype. Eur. J. Clin. Pharmacol. 1987; 33: 397
   PubMed Web of Science ®Google Scholar
• Steiner E., Alvan G., Garle M., Maguire J. H., Lind M. S., Nilson O., Tomson T., Mc J. S., Sjoqvist F. The debrisoquin hydroxylation phenotype does not predict the metabolism of phenytoin. Clin. Pharmacol. Ther. 1987; 42: 326
   PubMed Web of Science ®Google Scholar
• Schellens J. H. M., Van der Wart J. H. F., Breimer D. D. Relationship between mephenytoin oxidation polymorphism and phenytoin, methylphenytoin and phenobarbitone hydroxylation assessed in a phenotyped panel of healthy subjects. Br. J. Clin. Pharmacol. 1990; 29: 665
   PubMed Web of Science ®Google Scholar
• Srivastava P. K.C., Yun H., Beaune P. H., Ged C., Guengerich F. P. Separation of human liver tolbutamide hydroxylase and (S)-mephenytoin 4′-hydroxylase cytochrome P-450 enzymes. Mol. Pharmacol. 1991; 40: 69
   PubMed Web of Science ®Google Scholar
• Wrighton S. A., Stevens J. C., Becker G. W., Vanden-Branden M. Isolation and characterization of human liver cytochrome P450 2C19: Correlation between 2C19 and S-mephenytoin 4-hydroxylation. Arch. Biochem. Biophys. 1993; 306: 240
   PubMed Web of Science ®Google Scholar
• Daly A. K., Cholerton S., Gregory W., Idle J. R. Metabolic polymorphisms. Pharmacol. Ther. 1993; 57: 129
   PubMed Web of Science ®Google Scholar
• Shepard D. R., Krecic M. E., Boyd R. T., Mays D. C., Curtiss A., Raucy J. L., Lasker J. M., Gerber N. Metabolism of phenytoin by hepatic microsomes, purified cytochrome P450s and P450s expressed in COS-1 cells. Pharmacologis. 1993; 35: 203
   Google Scholar
• Glazko A. J. Diphenylhydantoin metabolism. Drug Metab. Dispos. 1973; 1: 711
   PubMed Web of Science ®Google Scholar
• Maguire J. H. Quantitative estimation of catechol/methylcatechol pathways in human phenytoin metabolism. Epilepsi. 1988; 29: 753
   Google Scholar
• Thompson R. M., Beghin J., Fife W. K., Gerber N. 5,5-Bis(4-hydroxyphenyl)hydantoin, a minor metabolite of diphenylhydantoin (Dilantin) in the rat and human. Drug Metab. Dispos. 1976; 4: 349
   PubMed Web of Science ®Google Scholar
• Billings R. E., Fischer L. J. Oxygen-18 incorporation studies of the metabolism of phenytoin to the catechol. Drug Metab. Dispos. 1985; 13: 312
   PubMed Web of Science ®Google Scholar
• Billings R. E. Sex differences in rats in the metabolism of phenytoin to 5-(3,4-dihydroxyphenyl)-5-phenylhydantoin. J. Pharmacol. Exp. Ther. 1983; 225: 630
   PubMed Web of Science ®Google Scholar
• Maguire J. H., Wilson D. C. Urinary dihydrodiol metabolites of phenytoin: High-performance liquid chromatographic assay of diastereomeric composition. J. Chromatogr. Biomed. Appl. 1985; 342: 323
   Google Scholar
• Krecic M. E., Shepard D. R., Mays D. C., Raucy J. L., Lasker J. M., Gerber N. Measurement of the stereoselective metabolism of phenytoin using an S-hydroxypropyl (3-cyclodextrin column. Pharmacologis. 1993; 35: 203
   Google Scholar
• Weinshilboum R. M. Human pharmacogenetics of methyl conjugation. Fed. Pro. 1984; 43: 2303
   PubMedGoogle Scholar
• Kroetz D. L., Kerr B. M., Mc L. V., Loiseau P., Wilensky A. J., Levy R. H. Measurement of in vivo microsomal epoxide hydrolase activity in White subjects. Clin. Pharmacol. Ther. 1993; 53: 306
   PubMed Web of Science ®Google Scholar
• Kutt H., Wolk M., Scherman R., Mc F. Insufficient parahydroxylation as a cause of diphenylhydantoin toxicity. Neurolog. 1964; 14: 542
   PubMed Web of Science ®Google Scholar
• Vasko M. R., Bell R. D., Daly D. D., Pippenger C. E. Inheritance of phenytoin hypometabolism: A kinetic study of one family. Clin. Pharmacol. Ther. 1980; 27: 96
   PubMed Web of Science ®Google Scholar
• Vermeij P., Ferrari M. D., Buruma O. J. S., Veenema H., de Wolff F. A. Inheritance of poor phenytoin parahydroxylation capacity in a Dutch family. Clin. Pharmacol. Ther. 1988; 44: 588
   PubMed Web of Science ®Google Scholar
• Arnold K., Gerber N. The rate of decline of diphenylhydantoin in human plasma. Clin. Pharmacol. Ther. 1970; 11: 121
   PubMed Web of Science ®Google Scholar
• Andoh B., Idle J. R., Sloan T. P., Smith R. L., Woolhouse N. Inter-ethnic and inter-phenotype differences among Ghanaians and Caucasians in the metabolic hydroxylation of phenytoin. Br. J. Clin. Pharmacol. 1980; 8: 282P
   Google Scholar
• Miller R., Rheeders M., Klein C., Suchet I. Population pharmacokinetics of phenytoin in South African Black patients, 5. Afr. Med. J. 1987; 72: 188
   PubMed Web of Science ®Google Scholar
• Nhachi C. F. B., Mwaluko G. M. P. Some characteristics of serum phenytoin concentration in Black Zimbabwean volunteers. E. Afr. Med. J. 1992; 69: 693
   PubMed Web of Science ®Google Scholar
• Scott J., Poffenbarger P. L. Pharmacogenetics of tolbutamide metabolism in humans. Diabete. 1979; 28: 41
   Google Scholar
• Page M. A., Boutagy J. S., Shenfield G. M. A screening test for slow metabolizers of tolbutamide. Br. J. Clin. Pharmacol. 1991; 32: 649
   Google Scholar
• Pollock B. G., Perel J. M., Kirshner M., Altieri L. P., Yeager A. L., Reynolds C. F. III, S-Mephenytoin 4-hydroxylation in older Americans. Eur. J. Clin. Pharmaco. 1991; 40: 609
   PubMed Web of Science ®Google Scholar
• Huang D., Tsai J. No bimodal distribution of urinary SIR ratios of phenytoin hydroxylation phenotype in Chinese patients. Eur. J. Pharmaco. 1990; 183: 1072
   Web of Science ®Google Scholar
• Horai Y., Nakano M., Ishizaki T., Ishikawa K., Zhou H. H., Zhou B. J., Liao C. L., Zhang L. M. Metroprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin. Pharmacol. Ther. 1989; 46: 198
   PubMed Web of Science ®Google Scholar
• Nakamura K., Goto F., Ray W. A., Mc C. B., Jacqz E., Wilkinson G. R., Branch R. A. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin. Pharmacol. Ther. 1985; 38: 402
   PubMed Web of Science ®Google Scholar
• Grasela T. H., Sheiner L. B., Rahbek B. Steady state pharmacokinetics of phenytoin from routinely collected patient data. Clin. Pharmacokinet. 1983; 8: 355
   PubMed Web of Science ®Google Scholar
• Chan E., Ti T. Y., Lee H. S. Population pharmacokinetics of phenytoin in Singapore Chinese. Eur. J. Clin. Pharmaco. 1990; 39: 177
   PubMed Web of Science ®Google Scholar
• Yukawa E., Higuchi S., Aoyama T. Population pharmacokinetics of phenytoin from routine clinical data in Japan: An update. Chem. Pharmaceut. Bul. 1990; 38: 1973
   PubMed Web of Science ®Google Scholar
• El-Sayed Y. M., Islam S. I. Phenytoin Michaelis-Menten pharmacokinetics in Saudi patients. Int. J. Clin. Pharm. 1989; 27: 173
   Google Scholar
• Bauer L. A., Blouin R. A. Phenytoin Michaelis-Menten pharmacokinetics in Caucasian paediatric patients. Clin. Pharmacokinet. 1983; 8: 545
   PubMed Web of Science ®Google Scholar
• Chiba K., Ishizaki T., Miura H., Minagawa K. Michaelis-Menten pharmacokinetics of diphenylhydantoin and application in the pediatric age patient. J. Pediatr. 1980; 96: 479
   PubMed Web of Science ®Google Scholar
• Kromann N., Christiansen J., Flachs H., Dam M., Hvidberg E. F. Differences in single dose phenytoin kinetics between Greenland Eskimos and Danes. Ther. Drug Monit. 1981; 3: 239
   PubMed Web of Science ®Google Scholar
• Voseh S., Muir K. T., Sheiner L. B., Follath F. Predicting individual phenytoin dosage. J. Pharmacokinet. Biopharm. 1981; 9: 131–147
   PubMedGoogle Scholar
• Ismail R., Rahman A. F. A. Michaelis-Menten pharmacokinetics of phenytoin in adult Malasian patients. J. Clin. Pharm. Ther. 1990; 15: 411
   PubMed Web of Science ®Google Scholar
• Vessell E. S., Page J. G. Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man. J. Clin. Invest. 1969; 48: 2202
   PubMed Web of Science ®Google Scholar
• Dickinson R. G., Hooper W. D., Patterson M., Eadie J. J., Maguire B. Extent of urinary excretion of p-hydroxyphenytoin in healthy subjects given phenytoin. Ther. Drug Monit. 1985; 7: 283–289
   PubMed Web of Science ®Google Scholar
• Miller R., Bill P. L. A., Du J. Phenytoin auto-induction?. S. Afr. Med. J. 1989; 75: 332
   PubMed Web of Science ®Google Scholar
• Glazko A. J., Peterson F. E., Chang T., Dill W. A., Smith T. C., Buchanan R. A. Phenytoin metabolism in subjects with long and short plasma half-lives. Ther. Drug Monit. 1982; 4: 281
   PubMed Web of Science ®Google Scholar
• Dhar G. J., Ahamed P. N., Pierach C. A., Howard R. B. Diphenylhydantoin-induced hepatic necrosis. Postgrad. Med. 1974; 56: 128
   PubMed Web of Science ®Google Scholar
• Parker W. A., Shearer C. A. Phenytoin hepatotoxicity: A case report and review. Neurolog. 1979; 29: 175
   PubMed Web of Science ®Google Scholar
• Mullick F. G., Ishak K. G. Hepatic injury associated with di-phenylhydantoin therapy. Am. J. Clin. Pathol. 1980; 74: 442
   PubMed Web of Science ®Google Scholar
• Smythe M. A., Umstead G. S. Phenytoin hepatotoxicity: A review of the literature. DICP Ann. Pharmacother. 1989; 23: 13
   PubMedGoogle Scholar
• Braverman I. M., Levin J. Dilantin-induced serum sickness: Case report and inquiry into its mechanism. Am. J. Med. 1963; 35: 418
   PubMed Web of Science ®Google Scholar
• Spielberg S. P., Gordon G. B., Blake D. A., Mellits E. D., Bross D. S. Anticonvulsant toxicity in vitro: Possible role of arene oxides. J. Pharmacol. Exp. Ther. 1981; 217: 386
   PubMed Web of Science ®Google Scholar
• Spielberg S. P., Gordon G. B., Blake D. A., Goldstein D. A., Herlong F. Predisposition to phenytoin hepatotoxicity assessed. in vitro, N. Engl. J. Med. 1981; 305: 722–727
   PubMed Web of Science ®Google Scholar
• Shear N. H., Spielberg S. P. Anticonvulsant hypersensitivity syndrome: In vitro assessment of risk. J. Clin. Invest. 1988; 82: 1826
   PubMed Web of Science ®Google Scholar
• Gennis M. A., Vemuri R., Burnes E. A., Hill J. V., Miller M. A., Spielberg S. P. Familial occurrence of hypersensitivity to phenytoin. Am. J. Med. 1991; 91: 631
   PubMed Web of Science ®Google Scholar
• Strickler S. M., Dansky L. V., Miller M. A., Seni M. H., Andermann E., Spielberg S. P. Genetic predisposition to phenytoin-induced birth defects. Lancet 1985; 2: 746–749
   PubMed Web of Science ®Google Scholar
• Guengerich F. P., Turvy C. G. Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J. Pharmacol. Exp. Ther. 1991; 256: 1189
   PubMed Web of Science ®Google Scholar
• Hansen D. K. The embryotoxicity of phenytoin: An update on possible mechanisms. Proc. Soc. Exp. Biol. Med. 1991; 197: 361–368
   PubMed Web of Science ®Google Scholar
• Van D. C., Berg M. J., Olson C. H. Differences in phenytoin biotransformation and susceptibility to congenital malformations: A review. D1CP Ann. Pharmacother. 1991; 25: 987–992
   PubMed Web of Science ®Google Scholar
• Finnell R. H., Buehler B. A., Kerr B. M., Ager P. L., Levy R. H. Clinical and experimental studies linking oxidative metabolism to phenytoin-induced teratogenesis. Neurolog. 1992; 42: 25
   PubMed Web of Science ®Google Scholar
• Rane A., Peng D. Phenytoin enhances epoxide metabolism in human fetal liver cultures. Drug Metab. Dispos. 1985; 13: 382
   PubMedGoogle Scholar
• Wells P. G., Jubovits J. T., Wong S. T., Molinari L. M., Ali S. Modulation of phenytoin teratogenicity and embryonic covalent binding by acetylsalicyclic acid, caffeic acid, and a-phenyl-A/J-butyl-nitrone: Implications for bioactivation by prostaglandin synthetase. Toxicol. Appl. Pharmacol. 1989; 97: 192
   PubMed Web of Science ®Google Scholar
• Roy D., Snodgrass W. R. Covalent binding of phenytoin to protein and modulation of phenytoin metabolism by thiols in A/J mouse liver microsomes. J. Pharmacol. Exp. Ther. 1990; 252: 895
   PubMed Web of Science ®Google Scholar
• Leeder J. S., Riley R. J., Cook V. A., Spielberg S. P. Human anti-cytochrome P450 antibodies in aromatic anticonvulsant-in-duced hypersensitivity reactions. J. Pharmacol. Exp. Ther. 1992; 263: 360
   PubMed Web of Science ®Google Scholar
• Riley R. J., Smith G., Wolf C. R., Cook V. A., Leeder J. S. Human anti-endoplasmic reticulum autoantibodies produced in aromatic anticonvulsant hypersensitivity reactions recognise rodent CYP3A proteins and a similarly regulated human P450 enzyme(s). Biochem. Biophys. Res. Commun. 1993; 191: 32
   PubMed Web of Science ®Google Scholar
• Wong D. D., Longenecker R. G., Liepman M., Baker S., La M. Phenytoin-dexamethasone: A possible drug-drug interaction. J. Am. Med. Asso. 1985; 254: 2062–2063
   Web of Science ®Google Scholar
• Lackner T. E. Interaction of dexamethasone with phenytoin. Pharmacotherap. 1991; 11: 344
   PubMed Web of Science ®Google Scholar
• De L. D., Kaplowitz N. Glutathione metabolism and its role in hepatotoxicity. Pharmacol. Ther. 1991; 52: 287
   PubMed Web of Science ®Google Scholar
• Board P., Coggan M., Johnston P., Ross V., Suzuki T., Webb G. Genetic heterogeneity of the human glutathione transferases: A complex of gene families. Pharmacol. Ther. 1990; 48: 357
   PubMed Web of Science ®Google Scholar
• Billings R. E., Milton S. G. Conversion of phenytoin to reactive metabolites in rat liver microsomes. Adv. Exp. Med. Biol. 1986; 197: 931–939
   PubMedGoogle Scholar